@Article{,
AUTHOR = {Mehmet Asim Bilen, Adriana Reyes, Deb Bhowmick, 
April Maa, Robert Bast, Jr, Louis L. Pisters, 
Sue-Hwa Lin, Christopher J. Logothetis, Shi-Ming Tu},
TITLE = {Variant prostate carcinoma and elevated serum CA-125},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {21},
YEAR = {2014},
NUMBER = {5},
PAGES = {7442--7448},
URL = {http://www.techscience.com/CJU/v21n5/61386},
ISSN = {1488-5581},
ABSTRACT = {<b>Introduction:</b> About 10% of tumors derived from nongynecologic, noncoelomic tissues react with the OC125 antibody. Some patients with advanced prostate cancer were found to have elevated serum CA-125 level.
<br/>
<b>Materials and methods:</b> We examined the clinical history of 11 patients with castration resistant prostate cancer and an elevated serum CA-125 level. Pathological review and immunohistochemical staining were performed on tumors from eight of these patients.
<br/>
<b>Results:</b> Patients with advanced prostate cancer and an elevated serum CA-125 level responded to androgen ablative therapy (median duration, 27 months). They were predisposed to develop persistent or recurrent urinary symptoms and visceral metastases. Eight of 11 patients had a low or undetectable serum prostate-specific antigen level (≤4 ng/mL) or an elevated serum carcinoembryonic antigen level (>6 ng/mL). In 3 of 7 patients whose specimens were available for further review, the tumors contained histologic features compatible with a diagnosis of ductal or endometrioid adenocarcinoma of the prostate.
<br/>
<b>Conclusions:</b> Patients with prostate cancer and an elevated serum CA-125 level have unique clinical and pathologic characteristics. Some of these patients possess tumors compatible with a subtype of prostate cancer known as ductal adenocarcinoma. Additional studies need to be performed to elucidate the biologic basis of the various subtypes of prostate cancer.},
DOI = {}
}